Your browser doesn't support javascript.
loading
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Spring, L M; Tolaney, S M; Fell, G; Bossuyt, V; Abelman, R O; Wu, B; Maheswaran, S; Trippa, L; Comander, A; Mulvey, T; McLaughlin, S; Ryan, P; Ryan, L; Abraham, E; Rosenstock, A; Garrido-Castro, A C; Lynce, F; Moy, B; Isakoff, S J; Tung, N; Mittendorf, E A; Ellisen, L W; Bardia, A.
Afiliación
  • Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Fell G; Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Bossuyt V; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Abelman RO; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Wu B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Maheswaran S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Trippa L; Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Comander A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Mulvey T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • McLaughlin S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Ryan P; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Ryan L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Abraham E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Rosenstock A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Garrido-Castro AC; Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Lynce F; Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Moy B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Isakoff SJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
  • Tung N; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.
  • Mittendorf EA; Brigham and Women's Hospital, Harvard Medical School, Boston.
  • Ellisen LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Ludwig Center, Harvard Medical School, Boston, USA.
  • Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston. Electronic address: Bardia.Aditya@mgh.harvard.edu.
Ann Oncol ; 35(3): 293-301, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38092228
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Camptotecina / Inmunoconjugados / Anticuerpos Monoclonales Humanizados / Neoplasias de la Mama Triple Negativas Límite: Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Camptotecina / Inmunoconjugados / Anticuerpos Monoclonales Humanizados / Neoplasias de la Mama Triple Negativas Límite: Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido